Virtu Financial LLC Buys Shares of 66,717 Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Virtu Financial LLC acquired a new stake in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 66,717 shares of the biopharmaceutical company’s stock, valued at approximately $36,000. Virtu Financial LLC owned 0.12% of Marinus Pharmaceuticals at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. World Investment Advisors LLC bought a new position in shares of Marinus Pharmaceuticals during the third quarter worth about $104,000. Deltec Asset Management LLC acquired a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at approximately $107,000. JPMorgan Chase & Co. boosted its position in shares of Marinus Pharmaceuticals by 1,968.5% during the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 126,752 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in Marinus Pharmaceuticals by 39.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 117,255 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in Marinus Pharmaceuticals by 34.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after acquiring an additional 1,219,871 shares during the period. 98.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Marinus Pharmaceuticals in a research report on Wednesday, March 26th. They set a “sell” rating for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of MRNS opened at $0.55 on Wednesday. The firm’s 50 day moving average is $0.55 and its 200-day moving average is $0.70. Marinus Pharmaceuticals, Inc. has a 12-month low of $0.22 and a 12-month high of $9.03. The stock has a market capitalization of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.